Frederike Kramer

My current research explores the mechanisms by which epigenetic mutations drive the progression of myeloproliferative neoplasms (MPN). Throughout my graduate and now postgraduate development, my research focused on the biology and pathogenesis of MPN. After completing my BSc and MSc in Biotechnology, I pursued my doctoral training at Charité in Berlin, Germany, and completed my PhD at Freie Universität Berlin with summa cum laude. My graduate work focused on platelet-derived growth factor receptor signaling in myelofibrosis, the most aggressive type of MPN. Building on my prior experience in blood cancer research, I joined Prof. Ann Mullally’s laboratory at Brigham and Women’s Hospital for my postdoctoral training. Here, I am investigating the role of ASXL1 mutations during progression of MPN using mouse and human model systems.